Cyclophosphamide teratogenesis: evidence for compensatory responses to induced cellular toxicity. 1990

B M Francis, and J M Rogers, and K K Sulik, and A J Alles, and K H Elstein, and R M Zucker, and E J Massaro, and M B Rosen, and N Chernoff
Developmental Toxicology Division, Environmental Protection Agency, Research Triangle Park, North Carolina 27711.

Cyclophosphamide (CP) administered ip to pregnant mice on day 10 of gestation (day of plug = day 0) is teratogenic (exencephaly, cleft palate, and limb malformations) at 20 mg/kg and embryolethal at higher doses. In the present study, CP was administered at 1, 5, 10, or 20 mg/kg on day 10 of gestation. Embryos were removed at 8 and 28 hr postdosing, and two embryos from each litter were immediately stained with Nile blue sulfate (NBS) to identify areas of cell death. The remaining embryos were frozen and forelimb buds subsequently removed for flow cytometric (FCM) analysis of the cellular DNA synthetic cycle. Additional litters were examined near term (day 17) for morphological abnormalities; these data were correlated with embryonic toxicity as detected by NBS staining and FCM analysis. Only the highest dose produced malformations. In marked contrast, a dose-related increase in the percentage of limb bud cells in the S (DNA synthetic) phase of the cell cycle was detectable at all doses. Inhibition of DNA synthesis was detected at all doses 8 hr post exposure and persisted through 28 hr for doses greater than or equal to 10 mg/kg. NBS staining indicated increased cell death in the alar plate of the neural tube 28 hr after exposure to 10 mg/kg CP and generally increased cell death in areas of rapid cell proliferation throughout the embryo at 20 mg/kg. The absence of an overt teratogenic response at dose levels that produced significant perturbation of the cell cycle indicates that a measure of embryonic damage can be compensated for or repaired. The implications of these findings for the existence of thresholds in developmental toxicity are discussed.

UI MeSH Term Description Entries
D008431 Maternal-Fetal Exchange Exchange of substances between the maternal blood and the fetal blood at the PLACENTA via PLACENTAL CIRCULATION. The placental barrier excludes microbial or viral transmission. Transplacental Exposure,Exchange, Maternal-Fetal,Exposure, Transplacental,Maternal Fetal Exchange
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females

Related Publications

B M Francis, and J M Rogers, and K K Sulik, and A J Alles, and K H Elstein, and R M Zucker, and E J Massaro, and M B Rosen, and N Chernoff
March 2003, Toxicology letters,
B M Francis, and J M Rogers, and K K Sulik, and A J Alles, and K H Elstein, and R M Zucker, and E J Massaro, and M B Rosen, and N Chernoff
November 2003, La Revue du praticien,
B M Francis, and J M Rogers, and K K Sulik, and A J Alles, and K H Elstein, and R M Zucker, and E J Massaro, and M B Rosen, and N Chernoff
July 1989, The Journal of rheumatology,
B M Francis, and J M Rogers, and K K Sulik, and A J Alles, and K H Elstein, and R M Zucker, and E J Massaro, and M B Rosen, and N Chernoff
January 1985, Teratogenesis, carcinogenesis, and mutagenesis,
B M Francis, and J M Rogers, and K K Sulik, and A J Alles, and K H Elstein, and R M Zucker, and E J Massaro, and M B Rosen, and N Chernoff
July 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience,
B M Francis, and J M Rogers, and K K Sulik, and A J Alles, and K H Elstein, and R M Zucker, and E J Massaro, and M B Rosen, and N Chernoff
January 1995, Teratogenesis, carcinogenesis, and mutagenesis,
B M Francis, and J M Rogers, and K K Sulik, and A J Alles, and K H Elstein, and R M Zucker, and E J Massaro, and M B Rosen, and N Chernoff
January 2004, Molecular and cellular biochemistry,
B M Francis, and J M Rogers, and K K Sulik, and A J Alles, and K H Elstein, and R M Zucker, and E J Massaro, and M B Rosen, and N Chernoff
January 1986, The British journal of cancer. Supplement,
B M Francis, and J M Rogers, and K K Sulik, and A J Alles, and K H Elstein, and R M Zucker, and E J Massaro, and M B Rosen, and N Chernoff
January 2005, Toxicology mechanisms and methods,
B M Francis, and J M Rogers, and K K Sulik, and A J Alles, and K H Elstein, and R M Zucker, and E J Massaro, and M B Rosen, and N Chernoff
June 2003, Birth defects research. Part A, Clinical and molecular teratology,
Copied contents to your clipboard!